Cancer immunotherapy has now entered clinical practice and has reshaped the standard of
care for many cancer patients. With these new strategies, specific toxicities have emerged …

Nephrotoxicity associated with immunotherapy is increasingly being encountered in clinical
practice. Drugs that augment the immune system to eradicate cancer are revolutionary in the …

Immune checkpoint inhibitors (ICI) are now widely used in the treatment of many cancers,
and currently represent the standard of care for multiple malignancies. These agents …

Nephrotoxicity from cancer therapies is common and increasingly encountered in clinical
practice, such that the subfield of “onco-nephrology” has emerged. Conventional …

As a new type of anti-tumor immunotherapy, immune checkpoint inhibitors (ICIs) have
improved the prognosis of multiple malignancies. However, renal complications are …

Introduction: Advanced cancers that did not respond to chemotherapy were once a death
sentence, but now there are newer therapies utilizing the patient's own immune system to …

Since their introduction into clinical practice a decade ago, immune checkpoint inhibitors
(ICIs) have had an overwhelming impact on cancer treatment. Use of these agents in …

Renal toxicities have been increasingly recognized as complications of the immune
checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk …

Simple Summary The immune system has a natural ability to work against cancer cells;
however, in many cases this ability is insufficient, and cancers develop methods enabling …

Background: Recent advances in immune therapy have focused on several agents that
target tumor suppression; specifically, use of immune checkpoint inhibitors (ICIs), such as …